Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026)
Akebia Therapeutics' Accumulated Expenses was $109.8 million in Q2 2026, up 19.8% from $91.62 million a year earlier but down 12.2% from the prior quarter.
Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026) Analysis & Trends
At the end of FY2025, Accumulated Expenses at Akebia Therapeutics came in at $121.72 million, up 91.8% from FY2024.
- Accumulated Expenses shows a five-year compound annual growth rate of -1.4% (FY2020 to FY2025).
- In earlier years, Accumulated Expenses was $63.46 million in FY2024 (-6.3%), $67.74 million in FY2023 (-10.6%), $75.78 million in FY2022 (-30.5%) and $109.01 million in FY2021 (-16.5%).
- Quarterly Accumulated Expenses has moved between $51.08 million (Q1 2023) and $144.7 million (Q3 2021) over five years.
- Compared with a year earlier, Accumulated Expenses has increased for six straight quarters, with growth averaging 46.3% over the last eight quarters.
- The best year-over-year quarter for Accumulated Expenses over five years was Q3 2025 (growth of 103.8%); the worst was Q1 2023 (a decline of 55.3%).
- Per Business Quant data, AKBA's Accumulated Expenses in the three quarters before Q2 2026 was $125.06 million (Q1 2026), $121.72 million (Q4 2025) and $106.42 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Akebia Therapeutics | 250.00 Mn | -419.48 Mn | 38.70 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 109.80 Mn |
| Mar 31, 2026 | 125.06 Mn |
| Dec 31, 2025 | 121.72 Mn |
| Sep 30, 2025 | 106.42 Mn |
| Jun 30, 2025 | 91.62 Mn |
| Mar 31, 2025 | 71.34 Mn |
| Dec 31, 2024 | 63.46 Mn |
| Sep 30, 2024 | 52.22 Mn |
| Jun 30, 2024 | 53.90 Mn |
| Mar 31, 2024 | 53.91 Mn |
| Dec 31, 2023 | 67.74 Mn |
| Sep 30, 2023 | 62.66 Mn |
| Jun 30, 2023 | 56.41 Mn |
| Mar 31, 2023 | 51.08 Mn |
| Dec 31, 2022 | 75.78 Mn |
| Sep 30, 2022 | 92.53 Mn |
| Jun 30, 2022 | 95.01 Mn |
| Mar 31, 2022 | 114.24 Mn |
| Dec 31, 2021 | 109.01 Mn |
| Sep 30, 2021 | 144.70 Mn |
Akebia Therapeutics Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=AKBA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();